Roche Diagnostics, a World Leader in HIV Monitoring Tests, and ARK Diagnostics, Inc. Sign Letter of Intent to Commercialize ARK’s HIV Drug Monitoring Products

SUNNYVALE, Calif.--(BUSINESS WIRE)--ARK Diagnostics, Inc. (“ARK”), and Roche Diagnostics signed a letter of intent to negotiate a collaboration agreement that would grant Roche distribution and commercialization rights for ARK’s anti-HIV drug monitoring products. “We are pleased to partner with Roche Diagnostics — a world leader in diagnostics — to leverage its distribution and marketing strengths to quickly get the anti-HIV drug monitoring products to market,” said Johnny Valdez, president of ARK Diagnostics. “Roche will be immediately selling and distributing our products worldwide.”